TruthArchive.ai - Related Video Feed

Speaker 0 asks: first, what impacts the loss of bifidobacterium? and second, what can we do to replenish it and keep it strong and populated? Speaker 1 responds that the microbiome is still in its infancy, and urges not to assume you can test your stools in the market because the FDA doesn’t have a test approved for testing stool. Regarding buying Bifidobacterium, he says that the problem with replenishing is you may suppress your own ability to make Bifidobacteria, and what Bifidobacteria needs is good nutrition, good vitamins, and good yogurt. He cites the case of a woman who lived to 117 years old in India, noting that remnants of bifidobacteria were found in her stools, and that she ate yogurt three times a day. When asked how much she ate, he replies that there aren’t studies on that, but yogurt is happening. Speaker 1 continues: in a world where we constantly dodge viruses, parasites, and bacteria that secrete toxins, survival involves doing one’s best. There are things that kill the microbiome, notably antibiotics. Therefore, when you take antibiotics, that’s the time to supplement with a good probiotic and good vitamins. He notes a problem: 16 out of 17 probiotics on the market do not have Bifidobacteria. He explains why he began focusing on Bifidobacteria: in the trillion-dollar probiotic industry, if you turn a bottle around and read the ingredients, the bacteria listed are Bifidobacteria. That observation during the pandemic sparked his interest in Bifidobacteria. He says the whole path is to save the Biff, referencing the idea that during stressful moments—political division, hate, anger—seeing the power of a microbe becomes important.

A study comparing autistic children to their neurotypical siblings and unrelated neurotypical children revealed that autistic children often lack bifidobacteria, a crucial microbe abundant in newborns. The speaker is publishing a paper based on this research. Identical twins with autism, who were nonverbal and aggressive, shared elevated levels of three identical microbes and had zero bifidobacteria. After treatment focused on eliminating harmful microbes and increasing beneficial ones, both twins became fully verbal and non-aggressive within seven months. The speaker believes that the microbiome offers insights into the condition of these children, as microbes travel from the gut to the brain via nerves. The speaker emphasizes the need to focus on nonverbal, severely affected autistic children and criticizes the lack of research and therapeutics, especially in light of the high number of cases in California.

Case: a kid progressed from nonverbal to speaking, then to calmer behavior as his microbiome aligned with his sister. They are publishing a paper on 20 autistic children versus 23 neurotypical siblings and six non-neurotypical kids with no family history of autism. They found autistic kids lacked a very important microbe—bifidobacteria, the microbe newborns are born with; aging is loss of bifidobacteria. In these 20 autistic children, bifidobacteria were low or absent, unlike their siblings; even within the same household, neurotypical vs autistic, those inside fared worse, indicating gut dysbiosis. In two cases of identical twins, nonverbal and aggressive, the same three microbes were elevated at baseline, and both had zero bifidobacteria. Seven months later, the twins are verbal and non-aggressive. "Follow the microbiome" to see the answer; microbes travel from gut to brain. It is a crime to ignore that. California crisis; funding should go to research and therapeutics.

"in New Jersey, the rate of autism is one in thirty three, and we we are seeing a depletion of the microbiome." "New Jersey, one in thirty three." "one in ten thousand." "What happens in thirty years from now? Is it gonna be one in one?" "will there be a child born in this country that doesn't have autism?" "the disappearing microbes that I like to call the bifidobacteria disappearance." "I I told you at the beginning, bifidobacteria is important in helping us break down sugars." "What happens when it disappears? Right?" "You're going to have increased MECFS, right? Because they're tired." "MECFS have lots of bifidobacteria."

A woman with a dairy-free yogurt concept claimed to have bifidobacteria; I tested her microbiome. She didn't have any and had a history of cancer on top of that. And then I tested the yogurt, and the yogurt didn't have any bifidobacteria. Now here's a woman that bought into that whole yogurt, decided to make her own, trusted a factory from wherever to make it for her, and the factory scammed her and never made never put some bifidobacteria in there. So, you know, she had to change formula. Amazing story. “I mean, so we realized after you said 98% of the probiotics don't make it all the way to the large intestine.” “We'll not inoculate your large intestine with beneficial and you don't really you don't know what you're doing, so it could be actually more harmful than helpful.” “So that's why we decided to make the yogurt.” “It's kind of right now at the way and I try not to, you know, guide people because, really, everything I do is research.” “We are going to come out with something that's going to allow everyone to test. That's a cheap solution.” “That's great to for know.” “The end of the month.” “A cheap test that's gonna allow you to test your yogurt once and for all.” “If something is healthy then great keep doing that.” “If something is causing you gas, bloating, constipation, then stop it because that tells you right away that something's wrong with what you're doing.”

The speaker ties stool and fecal transplant to the brain–gut axis, recalling an N-of-one observation: giving the microbiome of a happy person to a patient with suicidal tendencies, UTIs, C. difficile, psoriasis appeared to reduce suicidality. They stress the finding is not reproducible and suggest a donor component. They recount a case where the donor—a yoga instructor and vegetarian—was evaluated and deemed a perfect candidate, illustrating the importance of donor health and history. They warn that too often we assume a neighbor is a good donor, while we may not know the donor’s mental state. The field is promising but with unknowns. The speaker asserts there is nothing more important in this life than understanding the microbiome, which will affect your life, affect your kids’ lives, and warns that if we don’t pay attention, microbes are taking over our bodies when we die and put us back into ground.

"When fecal transplant showed more than, you know, improving C." "And one of my patients with Alzheimer's started remembering his daughter's date of birth, I said, what did I do? I just changed the microbiome." "I used the wife's microbiome to the husband." "It wasn't about pushing stools for Alzheimer's, but what was causing Alzheimer's? What microbes was the culprit?" "What microbes could suppress that microbe That's the culprit." "Babies have a lot of bifidobacteria, this important microbe that helps us decompose sugar." "And we saw a lot of Bifidobacteria in newborns." "There is obviously a consensus in the medical field because there's a lot of gynecologists now that are using the secretions from the vagina of the mom and smearing it on the baby that is born with C section to just make them healthier in a way."

"I did a case where I did fecal transplant on a patient with Alzheimer's, and he could remember his daughter's date of birth six months after the procedure. So when I changed his microbiome, his poop in his colon, and gave him his wife's microbiome, who was super with it, started remembering things. So, when we start looking, and we're actually publishing stuff at ACG, because the deadline's today actually to publish for ACG American So, College of we have six abstracts coming up, and so we're showing the data on Alzheimer's, autism, long haulers. So, can't say vaccine injured because then it's not gonna be, you know, it's too controversial. So we have to stay within the but here's the problem. It should not be controversial. In order to advance science, in order to advance medicine, we need to be, better. We need to be better at listening"

"everybody is different." "We all have a fingerprint of our microbiome." "families are different." "the mom with triplets had an overgrowth of a certain group of microbes and the triplets, two of the triplets didn't have that microbe, but the one with autism had twice the amount of microbes that the mom had." "Engraftment determines success of a fecal transplant." "The kid started speaking, verbalizing." "We discovered that those people that had severe COVID had zero Bifidobacteria." "autistic kids have loss of bifidobacteria." "two identical twins, same exact microbes disappeared after nine months, and the Bifidobacteria goes up." "these kids are verbalizing, they're reading, they're counting." "Restoring the microbiome, saving the Bif, improving the bifidobacteria, and the kids are verbalizing." "this is a new revelation." "And I think it's going to be one of the biggest discoveries of this century in my opinion."

Speaker describes taking on two nonverbal twins in July ’24. The mom from Tennessee flew in to see him, and a patient‑doctor relationship formed. He realized the mom would do everything he told her to do, and she said, “I trusted you because I came to your clinic and I saw everything you're doing to do things right.” After achieving speech, the kids went from nonverbal to fully verbal. He notes they followed the protocol and succeeded. The mom saw his lab and the machines; this is a multi‑million‑dollar lab created to help bring products to market that help the microbiome and to understand the microbiome so that if you mess up your microbiome with product ABC, we potentially could know in the future how to restore that damage from product ABC. Are there certain

"Vitamin C improves gut Bifidobacteria in humans." "This was an incidental finding of my berythrombacteria increasing with vitamin C." "the only thing I've done different is I've been taking these enormous amounts of vitamin c." "Essentially, what we noticed was an increase in the bifidobacteria." "within twenty four hours of the infusion of the pills." "We created the Microbiome Research Foundation essentially to raise the funds to continue doing the research." "So when the vitamin C came on, it was really calling my colleagues and saying, have a protocol that is looking at the microbiome." "Our job was not to treat the kids." "We gave an informed consent." "we didn't need an IRB approved giving vitamin c to these kids." "We got these kids poop." "Our job was to look at what is vitamin c doing before and after." "before and after for nutraceuticals, pre and post vaccination, pre and post drugs, pre and post foods." "We tested 20 kids."

Out of a thousand samples analyzed in the last year, less than 5% had bifidobacteria, and one out of a thousand stool samples had lactobacillus. Both are believed to be very important microbes. The speaker poses the question of what happens when Bifidobacteria and lactobacillus disappear. They claim you can't absorb sugar or calcium, and asks what happens to the Krebs cycle and humanity. They suggest the loss of bifida bacteria may be linked to chronic disease.

Interviewer: But you you have had this case. I know that you're still working on publishing the research where you, you know, you did this with twins. And we know that, you know, the twin studies are very popular for a bunch of reasons because the genetics are identical. What happened? Researcher: So from COVID and from doing that N of one, which took time, and then from trying to get this familial FMT, I had these kids that were basically coming in with autism. And I have a lot of patients that come to me that have tried so many things. So this case was two twins with the mom flew in from Tennessee, and I basically innovated. And but I said to her, I said, me let look at the microbiome. What was amazing about this case, and it's going to be a breakthrough, I don't want to say too much because it's going to be published in October at the American College of Gastro, but essentially we saw the identical out of trillions of microbes, we saw elevation, relative abundance of microbes elevated the same three phylum in both identical kids. And as we refluralized the gut, not with fecal transplant, but with methods, we basically noticed that those microbes disappeared and the good bacteria came on at the same time as speech started. So this was a breakthrough case, and it's going to be a breakthrough for the FDA once they see that. And we're going to use that. So we're going to start doing familial fecal transplant with the FDA. But we're hoping that we can bring this other method after, while we're doing familial fecal transplant to get the data to understand because this could have been a fluke with these two kids kids. But we wanna try to reproduce these two kids to see if we can do this for other kids. Mhmm. And therefore, maybe run two protocols, one with familial FMT, fecal microbiota transplant or intestinal microbiota transplant, and then another one with this protocol to see can we do this more safer, better, less playing with poop? Because this doesn't play with poop. Interviewer: Well, the other aspect is also that, as we said at the beginning, everybody's different, And so I think this is actually kind of important. There isn't a of Researcher: one size fits Interviewer: all solution when it comes to this. Researcher: There isn't a microbiome. There's trillions of microbes. And I gave you the example with the fungus or it could be a fungal, you know, overgrowth. It could be a you know, even doctor Feingold, who was the beginning, who basically said, let's try vancomycin. Right? Researcher: He said, let's vancomycin for kids with autism, and he saw something with vancomycin. What he was seeing was a destruction of a microbiome and a suppression of microbes that secrete toxins, which decreased the aggressivity the aggressivity of the kid but did not restore the speech. It was but at least it gave a quality of life to the family to say, hey. Our kid is not banging his head on the wall. And so vancomycin got us to this level. Researcher: Right? But vancomycin is not a permanent solution. The solution is really to restore the gut to the way it was, and the challenge that we have is we do not know what it was before. So when you take a kid and he has a destroyed microbiome, you don't know what his fingerprint of his microbiome was before to reproduce him. Right? Researcher: And you're right. Everybody's different, so everybody may not need the same, but we need to be more precise.

Politics should not have anything to do with treating kids with autism, because autism affects Democrats, Republicans, independents, races, religions, sexes. One in twelve and a half boys in California have autism; we must pay attention and put hands on deck. This is a physician-initiated IND (investigational new drug) trial: as a physician, I'll look at each child and ask why it worked in this kid and why it didn't work in that kid, and what I can do for the child it didn’t help. This is frontline clinical trials where physicians try different approaches. I'm focusing on the microbiome and an answer with fecal transplant. But what about the kid without a microbiome abnormality, or with a neurological primary? What about the kid with inflammatory bowel disease with destroyed mucosa that needs fixing before implanting microbes? What about brain-gut connections and genetic problems? These are different ways to treat.

Speaker 0 explains that in the probiotic market, one out of 17 probiotics on the market has real bacteria in there, meaning 16 out of 17 say Bifidobacteria on the label but don’t actually have it. He adds that three out of 26 yogurts or drinks that say bifidobacteria on the market have bifidobacteria; the rest do not. He then asks about verification and testing. Speaker 1 asks if there is any way to know by looking at the label, and whether testing exists. Speaker 0 says you can call the lab Progena Biome to test, and there are other labs that do spot checks. He notes another problem: whether the microbe is alive or dead. Bifidobacteria in the gut are anaerobic, so exposing capsules to air may kill them, and stomach acid could also kill them before they reach the gut. He reframes the question: what does dead bacteria do to a live microbiome? He compares it to sleeping with corpses and suggests eventual effects on the microbiome and potential diseases, reflecting his viewpoint. Speaker 0 then raises another issue: by taking probiotics, are you suppressing your own gut production, similar to taking pancreatic enzymes which helps digestion but may shut down the pancreas’s own secretion? He questions whether taking oral enzymes could cause damage by reducing the body's own production. He explains that their approach is research-focused: they test patients with a stool test in the research world, then determine what the probiotic is doing, and implement a protocol with the right probiotic, the right prebiotic, the right bovine, and the right vitamins to see if the patient improves. If it works, great; if not, they reassess why the probiotic didn’t work—whether the probiotic was killed in the gut or interacted with certain bowel areas and became inactivated or transformed. Speaker 0 notes that he doesn’t talk about which probiotics upfront because they are still testing. He mentions several probiotics he is testing and acknowledges that not everybody responds similarly. They must understand why a probiotic works in some patients but not in others. Overall, the discussion centers on probiotic quality, viability, and personalized testing to determine effectiveness, along with concerns about dead bacteria, potential suppression of natural gut processes, and the need for ongoing research to explain variable patient responses.

FDA approves familial fecal transplants for autism research: "This is not a pharmaceutical product. This is using the stools of a healthy sibling into a kid that is autistic." "This is a physician initiated IND, investigative new drug" will allow comparison of autistic and neurotypical siblings to determine why it works in some kids and not others. Hazan highlights a twin case: "identical out of trillions of microbes, we saw elevation relative abundance of microbes elevated the same three phylum in both identical kids." Speech started. She says "There isn't a one size fits all solution when it comes to this" and calls for precise, collaborative research. She notes "the spike protein reduces bifidobacteria" and that "forty three severe patients with COVID had zero bifidobacteria," linking microbiome to disease resilience. "There is a microbiome" and "There isn't a microbiome. There's trillions of microbes."

Yes. But what a wonderful world, right, where you can manipulate the microbiome of a kid that's nonverbal, and all of a sudden, the kid's verbal. There is no better success story for me than that story when the mom called me and she goes, something's happening to my kids, doctor Hazen. Something's happening. You know all disease begins in the gut, and we got to start embarking, and I invite everyone. So when people come see me, it's not to see me as a physician, but it's really to embark with me on this research. And a lot of patients will say, I'm so excited to be part of your clinical trial, Doctor. Eason, because as I learn, they learn. So you know that I've always liked the cutting edge. I've always liked being ahead of everybody and thinking what's next.

Severely autistic, nonverbal twins were observed to have identical microbiome compositions. After correcting their microbiomes to increase good microbes and decrease bad microbes, the twins became verbal and fully reading. This outcome is considered significant because clinical improvement was correlated with a measurable improvement in the microbiome assay.

Speaker 1 discusses probiotics and the current state of microbiome science: taking random probiotics may be questionable because the technology of the microbiome is not FDA-approved yet. The reason is that there are many bacteria in the microbiome and we don’t know what they are, what they do, whether they’re good or bad. For example, blotia and Rosaburia are poorly understood; 90% of GI colleagues don’t know blotia is a microbe, and 90% don’t know there’s such a thing as Rosaburia. Historically trained on Klebsiella pneumoniae, E. coli, Salmonella, C. difficile, Clostridium perfringens, but not on nonpathogenic microbes. The question remains: is blotia a good bug or a bad bug, and who has too high or too low levels? This represents the abyss of the microbiome and is still research, not consumer product or standard medical practice. Speaker 1 explains that doctors cannot be told to use a new stool test or to start using microbiome data broadly until researchers reproduce findings and doctors see the data for themselves. The idea is that oncologists may notice correlations, such as loss of bifidobacteria in invasive cancer, and observe improvements in cancer alongside bifidobacteria, which could influence acceptance of the gut-brain or microbiome link. However, such observations need replication to move from incidental findings to established conclusions. An example given is Colleen Kelly at Brown University, who published two cases of alopecia areata with C. difficile where hair grew back after fecal transplant. The question is whether fecal transplant for alopecia areata is valid; however, an academic center trying to reproduce the data could not. The speaker suggests uncertainty about whether a specific microbe caused hair regrowth or if exposure during treatment led to it. Until data are reproduced, no one can claim alopecia areata is improved by fecal transplant or microbiota transplant. Concluding guidance: if you’re healthy, keep doing what you’re doing and do nothing else; if you’re not healthy and have multiple diseases and you’ve tried a probiotic, if it works, continue, but if it doesn’t work, then it’s probably not a great probiotic. The overarching theme is careful interpretation, replication, and recognition that microbiome science is still evolving and not yet ready for universal clinical application.

Dr. Feingold pioneered vancomycin and fecal transplants for autism, holding a patent with Dr. Barodi. The speaker began using fecal transplants to treat an autistic 17-year-old who was nonverbal and self-injurious, obtaining FDA approval for the case. The patient improved, speaking and ceasing self-harm. Feingold believed autism was caused by an overgrowth of *desulfa vibrio* or *Clostridium perfringens*. However, the speaker found *Lactobacillus animalis* and high proteobacteria levels, but no bifida bacteria in the patient, suggesting autism's microbial profile varies. Analyzing hundreds of stool samples from autistic children, the speaker aims to identify unnamed microbes linked to autism. Dr. Adams' fecal transplant capsules improved 50% of autistic children in a study, but 50% did not improve, suggesting multiple factors are at play. The speaker hypothesizes that donor compatibility is a factor in fecal transplant success for autism, though there is currently no data on this.

Out of a thousand samples analyzed in the last year, less than 5% had bifidobacteria, and one out of a thousand stool samples had lactobacillus. Both are considered very important microbes. The speaker asks what happens when Bifidobacteria and lactobacillus disappear, claiming that you can't absorb sugar or calcium, and questioning what happens to the Krebs cycle and humanity. The speaker suggests that the loss of bifida bacteria may be linked to chronic disease.

Bifidobacteria are important for immunity, but they are not the only important microbe. The speaker notes that bifidobacteria are the microbe that is disappearing. Analyzing thousands of stool samples, out of 4,000 stool samples, there are only four that can be said with certainty “these are both microbiomes.” Out of the thousand samples analyzed, less than five percent have bifidobacteria. The speaker highlights that loss of bifidobacteria is not universally linked to all conditions. It is present in Alzheimer's disease, with Alzheimer's patients having lots of bifidobacteria; Lyme disease patients also have lots of bifidobacteria. Crohn’s patients that have never been treated have lots of bifidobacteria. In autistic kids, there is enough data now; they showed data initially, and now more data and more labs reproducing that data show that there are lots of bifidobacteria in autism. The speaker mentions that “Loss of bifidobacteria in autism” can be addressed by replenishing bifidobacteria, and refers to this as proof of concept that the judge at the American College of Gastroenterology acknowledged, noting that this is what is needed to advance science to understand. Loss of bifidobacteria was also noticed in patients with invasive cancer. The speaker says they published that data at the American College of Gastroenterology and presented at Digestive Disease Week, showing that if a patient had a non-aggressive cancer, they had a better level of bifidobacteria than a patient with invasive cancer who has zero. Regarding therapeutic implications, the speaker asks whether modulating the gut to improve bifidobacteria is feasible and notes collaboration with multiple centers, including MD Anderson. The implication is to start modulating the gut and improving bifidobacteria in cancer patients rather than relying solely on chemotherapy and immunotherapy. In summary, the research conducted at Progena Biome—a research lab—focuses on bifidobacteria, its variable presence across diseases, its potential replenishment in autism, and its association with cancer progression, highlighting ongoing work to modulate the gut microbiome as a therapeutic strategy.

The speaker discusses striking clinical observations linking the microbiome, specifically Bifidobacteria, to major improvements in two areas: autism and cancer. They reference two twins with autism who were nonverbal. After improving and manipulating their microbiome, the twins are described as completely fully verbal and reading books, highlighting the potential power of Bifidobacteria in their treatment approach. The speaker then shifts to oncology, noting they recently finished speaking at the Win Consortium in front of academic oncologists. They presented data on a patient with stage four head and neck cancer who “shrunk by increasing the bifidobacteria,” emphasizing that the observed tumor response was attributed to the microbiome rather than surgery, chemotherapy, or radiation. This observation is described as illustrating “the power of the bifidobacteria.” Following this, the speaker describes how these findings are opening new collaborations with major cancer centers, specifically naming Penn State and MD Anderson, as oncologists recognize that while immunotherapy is being given, there is interest in long-term outcomes and better survival. The implication is that there may be an element being missed related to the microbiome. Finally, the speaker mentions ongoing research on neuroblastoma, focusing on Bifidobacteria and the broader microbiome to determine how immunotherapy can help on one side and how boosting the microbiome can help on the other. The overarching message is that “we tend to forget about the microbiome and immunity starts in the gut,” suggesting a central role for the gut microbiome in modulating immune responses and therapeutic outcomes.

The speaker investigated a commercially available microbe, typically given to infants in small doses. To increase the dosage, they created a yogurt-like substance to amplify the bacterial counts a thousandfold. The speaker observed effects in the mice they studied. Surprisingly, the speaker claims that every observation seen in mice has also been observed in humans.

Two twins with severe autism and nonverbal communication are described; their microbiome is identically the same, with the same groups of microbes. After you correct their microbiome, you flip that formula to becoming good microbes high, low bad microbes down. And those kids are speaking and fully verbal, fully reading, that's the gold. Because now you know, well, have clinical significance, but I also have a microbiome assay that tells me that my kid has improved. The speaker emphasizes 'the gold' as the result of these changes and references a microbiome assay to demonstrate improvement. This is presented as significant.